Trials of the cancer drug Stimuvax have been temporarily suspended because of safety concerns, biotechnology company Oncothyreon has announced.
The company said its partner Merck Serono had imposed the moratorium after a “suspected unexpected serious adverse reaction” in a patient, specifically inflammation of the brain.
Stimuvax is Oncothyreon’s lead drug candidate. The company currently has no products on the market.
Officials said a larger trial of the treatment, one focused on breast and lung cancer, had also been suspended.
Merck Serono is part of Germany pharmaceutical giant Merck.
Copyright Press Association 2010